Optimise drug screening processes

The most significant limitation to the development of new treatments in oncology is undoubtedly cost prohibition, as the attrition of a drug in the final stages of clinical trials carries significant financial implications for drug development.

The HuTrial platform enables drug discovery and development companies to optimise their screening processes to ensure that only the most effective candidates are accelerated through to the clinic and onto improving patient care.

Crown Bioscience Inc will showcase its human surrogate trial platform at the 50th Annual ASCO Conference, taking place in Chicago, US, between 30th May and 3rd June.

The HuTrial substitutes Phase-II trials at reduced cost, providing the opportunity for early decision making regarding drug candidate progression and significantly decreasing the risk of promoting ineffective therapeutics through the later stages of clinical testing.

The HuTrial platform substantially reduces the time and cost of phase-II trials and when used to identify patient biomarkers, it can effectively predict the clinical response of a prospective candidate before undergoing rigorous clinical testing. 

By evaluating all prospective treatments, surrogate trials can improve the success rate with which effective therapeutics reach the clinic and help reduce the chances of patients experiencing harmful or unpleasant side effects.

HuTrials are conducted using Crown’s HuPrime patient derived xenografts

HuTrials are conducted using Crown’s HuPrime patient derived xenografts (PDX), where primary tumour cells are extracted directly from a patient and transplanted into surrogate, in most cases immunodeficient mice. 

As the cancer develops, prospective treatments can be administered to the surrogate host and the efficacy of prospective drug candidates can be observed and evaluated.

Jean-Pierre Wery, the President of Crown Bioscience comments: “At Crown Bioscience we are committed to improving the decision making process involved in submitting drug candidates for phase II and III clinical trials. 

“As the most significant factor affecting the advancement of drug development is the cost of drug attrition in the later stages of clinical trials, it is important that we ensure that our clients do not waste resources on ineffective treatments. If we can assist them in identifying promising candidates early on, we can improve the rate at which effective new treatments are delivered into the clinic to improve patient outcomes. The 

“HuTrial platform has the potential to help alleviate the socio-economic burden cancer has on the healthcare industry and assist in the global effort to convert cancer from a terminal condition to a chronic disease.”

Recent Issues